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Summary (Word Count 200) 
Background:  Following resection, it is important to identify colon cancer patients at high-risk of 
recurrence, who may benefit from adjuvant treatment.  The Petersen Index (PI), a prognostic model 
based on pathological criteria is validated in Dukes B and C disease.  Similarly, the Glasgow-
Prognostic-Score (mGPS) based on biochemical criteria has also been validated.  This study 
compares both scores in patients undergoing curative resection of colon cancer. 
Methods:  244 patients underwent elective resection between 1997-2005.  PI was constructed from 
pathological reports; mGPS was measured pre-operatively.    
Findings:  Median follow-up was 67 months (minimum 36 months) during which 109 patients 
died; 68 from cancer.  On multivariate analysis of age, Dukes’ stage, PI and mGPS, age (HR, 1.74, 
P=0.001), Dukes’ stage (HR, 3.63, P<0.001), PI (HR, 2.05, P=0.010) and mGPS (HR, 2.34, 
P<0.001) were associated independently with cancer-specific-survival.  Three-year cancer-specific-
survival rates for Dukes B patients with low-risk PI were 98%, 92% and 82% for mGPS of 0, 1 and 
2 respectively (p<0.05).  
Interpretation:  The high-risk PI population is small, in particular Dukes’ B disease (10%).  mGPS 
further stratifies those classified as low-risk by PI.  Combining both scoring systems could identify 
patients who have undergone curative surgery but are at high-risk of cancer-related death, therefore 
guiding management and trial stratification.  
 
Keywords: Colorectal cancer, curative resection, Petersen Index, Glasgow Prognostic Score, 
survival. 
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Introduction 
Colorectal cancer is the second most common cause of cancer death in Western Europe and 
North America.  Each year in the UK, there are approximately 35,000 new cases and 16,000 deaths 
attributable to this disease.  Colon cancer accounts for majority of disease with approximately 
22,000 new cases and over 10, 000 deaths per year 1. Overall survival is poor; even in those who 
undergo resection with curative intent, only half survive five years 2.  
Whilst Dukes stage is widely used to predict outcome in colon cancer, it is also recognized 
that the survival of patients within the staging categories is variable, particularly those with Dukes B 
or T3/4 N0 tumours.  There is particular interest in identifying sub groups of patients with either 
Dukes’ stage B disease or Dukes’ C with only 1 positive node, who may be at relatively high or low 
risk respectively of developing recurrent cancer and therefore may or may not benefit from adjuvant 
chemotherapy 3.   
Consequently, considerable effort has been directed at refining prognostic criteria.  For 
example, numerous molecular-based factors have been evaluated 3. Clinically useful factors should 
be routinely available, well standardised and validated in a variety of different patient cohorts.  
However, few molecular-based factors satisfy these criteria and have been incorporated into routine 
clinical practice.  There remains a continuing need to identify clinically relevant factors that would 
improve the prediction of survival in patients undergoing potentially curative surgery for colon 
cancer. 
A score based on four routinely reported pathological criteria (vascular invasion, peritoneal 
involvement, margin involvement and tumour perforation), the Petersen Index (PI) has been 
reported to predict cancer-specific outcome in Dukes’ B colon cancer 4.  More recently, the PI has 
been validated as a prognostic score in patients undergoing potentially curative resection for both 
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Dukes’ B and C cancer of the colon and rectum 5.  Similarly, an inflammation-based score, based on 
two routinely measured acute phase proteins (C-reactive protein and albumin), the Glasgow 
Prognostic Score (GPS) has been reported to predict cancer-specific outcome in Dukes’ B colon 
cancer 
6
.  The GPS has recently been validated as a prognostic score in patients undergoing 
potentially curative resection for both Dukes’ B and C cancer of the colon 7.  To date, the 
relationship between the PI and the GPS has not been examined.  Moreover, the application of both 
scores to a single cohort of colon cancer patients has not previously been undertaken.   
The aim of the present study was to compare the prognostic value of the tumour-based 
(Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients 
undergoing resection for colon cancer. 
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Materials and methods 
Patients with histologically proven colon cancer who, on the basis of laparotomy findings 
and pre-operative abdominal computed tomography, were considered to have undergone potentially 
curative resection between January 1997 and July 2005 in a single surgical unit at the Royal 
Infirmary, Glasgow were included in the study.  These were consecutive, elective patients entered 
prospectively into a maintained database.  Exclusion criteria were: (i) emergency surgery (ii) death 
within 30 days of surgery, (iii) clinical evidence of infection or other inflammatory conditions such 
as inflammatory bowel disease or rheumatoid arthritis.  The tumours were staged using 
conventional Dukes’ classification 8. 
The Petersen Index was constructed from the scores allocated to the four selected 
pathological variables present in a tumour specimen.  Intra or extramural vascular invasion, 
peritoneal involvement and margin involvement were allocated a score of 1 and tumour perforation 
was allocated a score of 2.  The cumulative total is calculated and the PI considered low risk where 
the score is between 0 and 1 and high risk between 2 and 5 4 5. 
Blood samples were taken for routine laboratory measurements of albumin and C-reactive 
protein measurement prior to surgery.  This is standard practice in all cancer patients in our 
institution.  The coefficient of variation for these methods, over the range of measurement, was less 
than 5% as established by routine quality control procedures.  The GPS was constructed as 
previously described 9.  Briefly, patients with both an elevated C-reactive protein (>10mg/l) and 
hypoalbuminaemia (<35g/l) were allocated a score of 2.  Patients in whom only one of these 
biochemical abnormalities was present were allocated a score of 1.  Patients in whom neither of 
these abnormalities was present were allocated a score of 0.  Recently, however, the GPS has been 
modified based on evidence that hypoalbuminaemia, in patients with colorectal cancer without an 
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elevated C-reactive protein concentration, had no significant association with cancer specific 
survival.  Therefore, patients with an elevated C-reactive protein were assigned a modified GPS 
score (mGPS) of 1 or 2 depending on the absence or presence of hypoalbuminaemia 6. 
The provision of adjuvant treatment was at the discretion of the oncologist managing the 
patient following the multi-disciplinary team assessment.  Therefore, all biochemical and 
pathological results as well as patient comorbidities were available to the oncologist in making such 
decisions on adjuvant treatment. 
 The study was approved by the Research Ethics Committee, Royal Infirmary, Glasgow. 
 
Statistics 
Grouping of the variables was carried out using standard thresholds.  Univariate survival 
analysis was performed using the Kaplan–Meier method with the log-rank test.  Multivariate 
survival analysis and calculation of hazard ratios (HR) were performed using Cox’s proportional-
hazards model.  A stepwise backward procedure was used to derive a final model of the variables 
that had a significant independent relationship with survival.  To remove a variable from the model, 
the corresponding P-value had to be greater than 0.05.  Deaths up to August 1st 2008 were included 
in the analysis.  Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
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Results 
Baseline clinico-pathological characteristics and the relationship with 5 year survival rate of 
the patients (n= 244) who underwent curative surgery for colon cancer are shown in Table 1.  The 
majority of patients were 65 or older (73%), were male (52%), and had Dukes’ stage A/B disease 
(59%).  Fifty-six (23%) patients received adjuvant chemotherapy.  Median number of lymph nodes 
sampled was 14 (range 3-52) for Dukes’ B tumours and 14 (range 3-34) for Dukes’ C tumours.  The 
majority of patients had no evidence of vascular invasion (67%), peritoneal involvement (74%), 
resection margin involvement (91%) and tumour perforation (97%) and had a low risk Petersen 
Index (87%).  The majority of patients had C-reactive protein (51%) and albumin (83%) 
concentrations in the normal range and a normal mGPS (51%).  Of the 40 patients with 
hypoalbuminaemia, 31 (78%) had an elevated C-reactive protein concentration. 
The minimum follow-up was 36 months; the median follow-up of the survivors was 67 
months.  No patients were lost to follow up.  During this period 68 patients died of their cancer and 
a further 41 patients died of intercurrent disease.  The univariate survival analysis for baseline 
clinico-pathological characteristics are shown in Table 1.  On univariate survival analysis of 
individual variables, age (P<0.001), Dukes’ stage (P<0.001), vascular invasion (P<0.001), 
peritoneal involvement (P<0.001), resection margin involvement (P<0.001), tumour perforation 
(P<0.005) C-reactive protein (P<0.001) and albumin (P<0.05) were associated significantly with 
overall survival.  Both PI (P<0.001) and mGPS (P<0.001) were associated significantly with overall 
survival (Table 1).   
On univariate survival analysis of individual variables, age (P<0.001), Dukes’ stage 
(P<0.001), vascular invasion (P<0.001), peritoneal involvement (P<0.001), resection margin 
involvement (P<0.001), tumour perforation (P<0.005) C-reactive protein (P<0.001) and albumin 
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(P<0.005) were associated significantly with cancer specific survival.  On multivariate analysis of 
these significant variables age (HR, 1.80, 95% CI, 1.30–2.49, P<0.001), Dukes’ stage (HR, 3.14, 
95% CI, 1.82-5.40, P<0.001), vascular invasion (HR, 2.18, 95% CI, 1.25-3.82, P=0.006), C-reactive 
protein (HR, 2.09, 95% CI, 1.20-3.65, P=0.010) and albumin (HR, 2.33, 95% CI, 1.30-4.17, 
P=0.004) were associated independently with cancer specific survival.  On multivariate analysis of 
age, Dukes’ stage, PI and mGPS, age (HR, 1.74, 95% CI, 1.27-2.39, P=0.001), Dukes’ stage (HR, 
3.63, 95% CI, 2.13-6.18, P<0.001), PI (HR, 2.05, 95% CI, 1.19-3.56, P=0.010) and mGPS (HR, 
2.34, 95% CI, 1.65-3.31, P<0.001) were associated independently with cancer specific survival. 
Multivariate survival analysis in patients with Dukes’ stage B and stage C disease is shown 
in Table 2.  In those patients with Dukes’ B stage disease, age (P<0.05), PI (P<0.001) and mGPS 
(P<0.01) were associated independently with cancer specific survival.  In those patients with Dukes’ 
C stage disease, age (P<0.05) and mGPS (P<0.001) were associated independently with cancer 
specific survival.   
The relationships between the PI and mGPS and cancer-specific survival in Dukes B and C 
colon cancer are shown in Figures 1a, 1b and Figures 2a and 2b respectively.  The three year cancer 
specific survival rate for patients with low risk PI and Dukes’ B stage disease was 98%, 92% and 
82% for mGPS of 0, 1 and 2 respectively (p<0.05; Table 3).  The three year cancer-specific survival 
rate in all patients with Dukes’ C stage disease and a low risk PI was 84%, 46% and 10% for a GPS 
of 0, 1 and 2 respectively (p<0.001).  
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Discussion 
The PI was initially reported in Dukes’ B colon cancers 4.  To date only one other study has 
validated the PI as a prognostic score in Dukes’ B and C colon cancer as well as rectal cancer 5.  
The results of the present study further validate the PI in a different population of patients 
undergoing potentially curative resection for colon cancer.  Of the 244 colon cancer patients 
included in this study, only 17% were classified as having a high risk PI.  The present PI high-risk 
population among Dukes’ B cases was 9%; smaller than the 29% of colon cancer cases originally 
reported by Petersen 4, but is more comparable with the recent study by Morris and colleagues 5 who 
also reported 9% of Dukes’ B colon cancers and rectal cancers as having a high risk PI.   
The basis of these differences in the classification of high risk PI between the studies is 
unclear.  However, it may reflect differences in case mix or variability in reporting those factors that 
form the PI and discriminate between Dukes’ B and C cases.  In the Petersen study of Dukes’ B 
colon cancers the prevalence of venous invasion (extra and intramural) was 30%; in Morris’ paper 
of Dukes’ B and C patients with both colon and rectal cancers the prevalence of extramural venous 
was14% and in the present paper of colon cancers venous invasion was seen in 33% of colonic 
resections.  In the 3 studies peritoneal involvement was seen in 42% (Petersen), 14% (Morris) and 
26% (present study).  The number of lymph nodes can affect the Dukes’ staging and the mean 
number of lymph nodes harvested was 21, 11 and 14 in the 3 studies.  In the present study lymph 
node analysis was carried out using routine pathological techniques in the Department of Pathology, 
Glasgow Royal Infirmary.  However it is recognised that immunohostochemical staining may 
increase the number of lymph node metastases identified (ref).  Further work is required to examine 
the utility of the GPS following immunohistochemical staining of apparently node-negative colon 
cancer.  Finally a recent study from Australia reports a review of the slides by a single expert 
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pathologist of 82 patients reported to have Dukes’ B cancer but no evidence of either venous 
invasion or serosal involvement.  Serosal involvement and/or venous invasion were identified on 
review in 32% and these findings correlated with survival 10.  
In spite of these drawbacks in pathology reports both the present study and that of Morris 
and co-workers highlight the prognostic value of the PI.  In particular, given that the results of both 
studies were drawn from cases dissected and reported by a number of pathologists, including trainee 
pathologists, they are likely to be representative of ‘real world’ pathology reporting used to inform 
multi-disciplinary team meetings of high risk patients with colon cancer.  Therefore, we would 
recommend the PI should be reported routinely in patients having undergone resection for Dukes’ B 
colon cancer, for whom it was designed, where the hazard ratio for survival in our study was 
approximately 10. 
The present study shows for the first time that both tumour-based (PI) and inflammation-
based (GPS) scoring systems have independent prognostic value in patients undergoing potentially 
curative resection for colon cancer.  While the PI measurement is subject to variation in reporting, 
the pre-operative mGPS, based on standard reliable laboratory measurements, is objective and 
therefore there is likely to be little variation in reporting. 
It is of interest to consider how these results might be combined in a clinical context.  At 
present, patients with Dukes’ C tumours are offered adjuvant chemotherapy and those with Dukes’ 
A tumours are not.  All the relevant studies concur that the PI identifies Dukes’ B patients who are 
at high risk and arguably these patients should also be offered chemotherapy.  Morris has shown 
that patients with single node positive Dukes’ C tumours had a better prognosis than patients with 
Dukes’ B tumours with a PI of 1 or more.  In the present study, among patients with Dukes’ B 
tumours and Dukes’ C tumours with a single positive node and a low risk PI, a high risk mGPS 
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indicated a statistically significant poorer prognosis when compared to patients with pathologically 
similar tumours who had a low risk mGPS (Table 3).  Such high risk patients may therefore be 
thought to benefit from adjuvant chemotherapy.  Based on previous work, the present study was 
certainly powered for Dukes B (n=127) and Dukes C (n=99) analysis but not single node positive 
Dukes C analysis.  Therefore, further single node positive Dukes C patients are required to establish 
whether the PI or the mGPS have prognostic value in patients undergoing potentially curative 
resection for these tumours.   
The utility of the PI in predicting response to chemotherapy is not, to our knowledge, 
known.  In contrast, there is evidence that an elevated C-reactive protein of the mGPS not only 
identifies those patients which are increased risk of recurrent disease but also those patients who are 
likely to benefit from adjuvant chemotherapy 11.  Therefore, on the basis of the evidence available 
the mGPS should be included, together with the PI, in the post-operative multi-disciplinary 
assessment of patients with primary operable colon cancer and the stratification of patients entering 
randomised trials of adjuvant chemotherapy.   
The basis of the independent relationship between an elevated mGPS prior to surgery and 
poor long term cancer specific survival in patients with primary operable colon cancer is not clear.  
A plausible explanation is that an elevated mGPS may reflect compromised cell mediated immunity 
since an elevated C-reactive protein and hypoalbuminaemia are associated with lymphocytopenia 12 
and an impaired T-lymphocytic response in the tumour 13.  Furthermore, the presence of an elevated 
C-reactive protein concentration and hypoalbuminaemia have also been shown to be associated with 
upregulation of components of innate immune system, including complement and macrophage 
function 14 15.  In addition, it is known that as part of the systemic inflammatory response, there is a 
release of pro-inflammatory cytokines and growth factors which may promote tumour growth 16 17.  
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Therefore, the mGPS may reflect host responses that impact prognosis in colon cancer whereas the 
PI might be considered to provide prognostic information on tumour behaviour. 
In summary, the results of the present study validate the use of the Petersen Index in 
predicting cancer specific survival in patients undergoing elective potentially curative for Dukes’ B 
colon cancer.  Furthermore the results indicate that the mGPS further stratifies those patients with 
Dukes’ B and single node positive Dukes’ C cancers, classified as low risk by the PI.  The PI and 
the mGPS scoring systems could therefore be combined at a multidisciplinary meeting to identify 
those patients with colorectal cancer who have undergone potentially curative surgery but who are 
at high risk of cancer related death.   
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Table 1.  Clinicopathological characteristics in patients undergoing potentially curative resection 
for colon cancer:  Univariate survival analysis. 
 
 
 
Patients 
244 (%) 
Overall 3-year 
survival rate 
% (SE) 
P-value 
(log-rank) 
Cancer 3-year 
survival rate 
% (SE) 
P-value 
(log-rank) 
Age  <65 years 
        65-74years 
        >75years 
65 (27) 
72 (29) 
107 (44) 
95 (3) 
76 (5) 
61 (5) 
 
 
<0.001 
95 (3) 
84 (4) 
68 (5) 
 
 
<0.001 
Sex  female 
        Male 
118 (48) 
126 (52) 
70 (4) 
79 (4) 
 
0.416 
79 (4) 
81 (4) 
 
0.832 
Dukes Stage  A 
                      B 
                      C 
18 (7) 
127 (52) 
 99 (41) 
94 (5) 
85 (3) 
58 (5) 
 
 
0.001 
100 (0) 
90 (3) 
63 (5) 
 
 
<0.001 
Adjuvant therapy  no 
                              yes 
88 (77) 
56 (23) 
74 (3) 
77 (6) 
 
0.028 
81 (3) 
77 (6) 
 
0.906 
Date of Surgery 1997-2001 
                          2002-2005 
116 (48) 
128 (52) 
77 (4) 
73 (4) 
 
0.514 
81 (4) 
79 (4) 
 
0.773 
      
Pathological Characteristics 
  Vascular invasion      no 
                                     yes 
  Peritoneal involvement  no 
                                         yes 
  Margin involvement  no 
                                     yes 
  Tumour Perforation   no 
                                     yes 
 
163 (67) 
81 (33) 
180 (74) 
64 (26) 
221 (91) 
23 (9) 
308 (98) 
6 (2) 
 
83 (3) 
58 (5) 
81 (3) 
51 (6) 
76 (3) 
57 (10) 
75 (3) 
50 (25) 
 
 
<0.001 
 
0.001 
 
<0.001 
 
0.001 
 
86 (3) 
67 (5) 
86 (3) 
64 (6) 
82 (3) 
60 (10) 
81 (3) 
50 (25) 
 
 
<0.001 
 
<0.001 
 
<0.001 
 
0.002 
Biochemical Characteristics 
  C-reactive protein  <10mg/l 
                                >10mg/l 
  Albumin  >35g/l 
                  <35g/l 
 
125 (51) 
119 (49) 
204 (83) 
40 (17) 
 
86 (4) 
63 (4) 
78 (3) 
58 (8) 
 
 
<0.001 
 
0.001 
 
92 (3) 
68 (4) 
83 (3) 
67 (8) 
 
 
<0.001 
 
0.004 
      
Petersen Index   
  Low Risk 
  High Risk 
 
203 (87) 
41 (13) 
 
79 (3) 
54 (8) 
 
 
<0.001 
 
84 (3) 
61 (8) 
 
 
<0.001 
mGlasgow Prognostic Score 
  Low Risk (0) 
  Intermediate (1) 
  High Risk (2) 
 
125 (51) 
88 (36) 
31 (13) 
 
86 (3) 
68 (5) 
48 (9) 
 
 
 
<0.001 
 
92 (3) 
72 (5) 
57 (9) 
 
 
 
<0.001 
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Table 2.  Clinicopathological characteristics and 3 year cancer specific survival in patients 
undergoing potentially curative resection for Dukes B and Dukes C colon cancer:  Multivariate 
survival analysis. 
Dukes B n=127 (%) 3 yr Survival 
% (SE) 
Hazard ratio (95% 
CI) 
P-value 
Age  <65yr 
          65-74yr 
          >75yr 
37 
40 
50 
100 (0) 
92 (4) 
81 (6) 
 
 
1.87 (1.05-3.34) 
 
 
0.034 
Sex     Female 
          Male 
61 
66 
90 (4) 
91 (4) 
 
0.99 (0.39-2.51) 
 
0.984 
Adjuvant therapy   No 
                               Yes 
111 
16 
92 (3) 
81 (10) 
 
0.98 (0.22-4.44) 
 
0.979 
Petersen Index  Low  
                         High Risk 
115 
12 
94 (2) 
58 (14) 
 
9.61 (3.27-28.26) 
 
<0.001 
mGlasgow Prognostic Score  Low 0      
                                               Intermediate 1 
                                               High Risk 2 
62 
47  
18 
97 (2) 
87 (5) 
78 (10) 
 
 
2.15 (1.19-3.87) 
 
 
0.010 
Dukes C n=99 (%) 3 yr Survival 
% (SE) 
Hazard ratio (95% 
CI) 
P-value 
Age  <65yr 
          65-74yr 
          >75yr 
25 
25 
49 
88 (6) 
66 (10) 
48 (7) 
 
 
1.72 (1.08-2.75) 
 
 
0.022 
Sex     Female 
          Male 
49 
50 
62 (7) 
64 (7) 
 
1.25 (0.68-2.31) 
 
0.477 
Adjuvant therapy   No 
                               Yes 
59 
40 
54 (7) 
75 (7) 
 
0.92 (0.42-2.00) 
 
0.832 
Petersen Index       Low  
                               High Risk 
70 
29 
63 (6) 
63 (9) 
 
1.16 (0.60-2.24) 
 
0.655 
mGlasgow Prognostic Score  Low 0               
                                               Intermediate 1 
                                               High Risk 2 
50 
37 
12 
83 (6) 
51 (8) 
24 (13) 
 
 
2.80 (1.80-4.44) 
 
 
<0.001 
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Table 3.  The relationship between the low risk Petersen Index, and the mGlasgow Prognostic 
Score with 3-year survival (%) in patients undergoing potentially curative resection for Dukes B, 
single node positive Dukes C and Dukes C colon cancer. 
 
Dukes B 
 
Petersen Index 
Low Risk (n=115) 
 
Petersen Index 
High Risk (n=12) 
mGlasgow Prognostic Score 
  Low Risk (0) 
  Intermediate (1) 
  High Risk (2) 
 
98% (n=56) 
92% (n=42) 
82% (n=17)** 
 
82% (n=6)  
40% (n=5)* 
0% (n=1)** 
mGlasgow Prognostic Score (0-2) 94% (n=115) 58% (n=12) 
 
Dukes C 
 
Petersen Index 
Low Risk (n=70) 
 
Petersen Index 
High Risk (n=29) 
mGlasgow Prognostic Score 
  Low Risk (0) 
  Intermediate (1) 
  High Risk (2) 
 
84% (n=39) 
46% (n=24)*** 
10% (n=7)**** 
 
76% (n=11) 
62% (n=13) 
40% (n=5)*** 
mGlasgow Prognostic Score (0-2) 63% (n=70) 63% (n=29) 
 
*p<0.1, **p<0.05, ***p<0.01, ****p<0.001:  Association between increasing mGPS and cancer-
specific survival on univariate analysis. 
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Figure 1a:  The relationship between low and high risk Petersen Index (from top to bottom) and 
cancer specific survival in Dukes B colon cancer patients (P<0.001) 
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Figure 1b:  The relationship between increasing mGPS (from the top to bottom) and cancer specific 
survival in Dukes B colon cancer patients (P<0.05) 
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Figure 2a:  The relationship between low and high risk Petersen Index (from top to bottom) and 
cancer specific survival in Dukes C colon cancer patients (P=0.195) 
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Figure 2b:  The relationship between increasing mGPS (from the top to bottom) and cancer specific 
survival in Dukes C colon cancer patients (P<0.001) 
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